Skip to content
    Real-World Studies

    Most Patients With Follicular Lymphoma on 5-Year Watch-And-Wait Remain Untreated

    Salim et alHematological oncology

    Most Patients With Follicular Lymphoma on 5-Year Watch-And-Wait Remain Untreated
    In a nationwide real-world study utilizing data from the Danish National Lymphoma Registry and detailed healthcare records, investigators evaluated clinical characteristics and treatment trajectories in patients with follicular lymphoma (FL) managed with an initial, continuous watch-and-wait strategy for at least 5 years (WAW5). The optimal follow-up duration for this patient subset has remained undefined.
    Among the 393 included WAW5 patients, 271 (69%) remained untreated after a median follow-up of 5.3 years following the WAW5 timepoint. The cumulative incidences of treatment initiation across the cohort were 16% (95% CI 12%–20%) at 2 years, 28% (95% CI 24%–33%) at 5 years, and 38% (95% CI 32%–44%) at 10 years.
    To refine risk prediction for time to treatment (TTT) in stage II–IV disease, the researchers applied best subset selection in a 7:3 random-sampling training cohort. A multivariable Cox regression model incorporating the number of nodal areas and bone marrow involvement provided the best prognostic fit, forming the basis of the WAW5-TTT risk score. In the training cohort, the 5-year cumulative incidence of treatment initiation was 13% (95% CI 5%–21%) for low-risk, 37% (95% CI 26%–48%) for intermediate-risk, and 46% (95% CI 35%–58%) for high-risk patients (Gray's test p < 0.0001), findings that were confirmed in the test cohort.
    The authors concluded that because the majority of patients remain treatment-free beyond the 5-year mark, these data support considering either discontinuation of routine surveillance or transition to a flexible, need-driven follow-up schedule, potentially utilizing prognostic risk factors to guide individualized clinical decisions.

    Key Takeaways

    • Among 393 follicular lymphoma patients managed with initial watch-and-wait for at least 5 years, 69% (n = 271) remained untreated after a median post-5-year follow-up of 5.3 years, with 2-, 5-, and 10-year cumulative incidences of treatment initiation of 16% (95% CI 12%–20%), 28% (95% CI 24%–33%), and 38% (95% CI 32%–44%), respectively.
    • For patients with stage II–IV disease, the WAW5-TTT risk score based on number of nodal areas and bone marrow involvement stratified 5-year cumulative incidence of treatment initiation into 13% (95% CI 5%–21%) for low-risk, 37% (95% CI 26%–48%) for intermediate-risk, and 46% (95% CI 35%–58%) for high-risk groups (Gray's test p < 0.0001), with results confirmed in the test cohort.
    Read the original sourceHematological oncology